Nitazoxanide: a first-in-class broad-spectrum antiviral agent
about
Peramivir: A Novel Intravenous Neuraminidase Inhibitor for Treatment of Acute Influenza InfectionsClinical Implications of Antiviral Resistance in InfluenzaRole of Marine Natural Products in the Genesis of Antiviral AgentsUsing the Ferret as an Animal Model for Investigating Influenza Antiviral EffectivenessCompounds with anti-influenza activity: present and future of strategies for the optimal treatment and management of influenza. Part II: Future compounds against influenza virusBroad-spectrum agents for flaviviral infections: dengue, Zika and beyondPediatric Drug Nitazoxanide: A Potential Choice for Control of Zika.Progress of small molecular inhibitors in the development of anti-influenza virus agents.Investigational hemagglutinin-targeted influenza virus inhibitors.A Review of Experimental and Off-Label Therapies for Clostridium difficile InfectionOptions for improving effectiveness of rotavirus vaccines in developing countries.A review of treatment modalities for Middle East Respiratory Syndrome.Overview of the 3rd isirv-Antiviral Group Conference--advances in clinical managementInterplay between influenza A virus and host factors: targets for antiviral intervention.Antiviral therapy in seasonal influenza and 2009 H1N1 pandemic influenza: Korean experiences and perspectives.Influenza antivirals currently in late-phase clinical trial.Iminosugars: Promising therapeutics for influenza infection.Infectious disease. Combating emerging viral threats.Respiratory Infections in the U.S. Military: Recent Experience and ControlLow Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection.Broad-spectrum antivirals against viral fusion.Antiviral effect of theaflavins against caliciviruses.Current tools for norovirus drug discoveryAnti-norovirus therapeutics: a patent review (2010-2015).Recent Advances in the Discovery of Norovirus Therapeutics.Existing drugs as broad-spectrum and potent inhibitors for Zika virus by targeting NS2B-NS3 interaction.Broad-spectrum antiviral agents.Potential chemotherapeutic targets for Japanese encephalitis: current status of antiviral drug development and future challenges.Nitazoxanide is active against Mycobacterium leprae.Bibliometric Assessment of the Global Scientific Production of NitazoxanideNeurocysticercosis: a review on status in India, management, and current therapeutic interventions.Norovirus in Transplantation.Biochemical Evaluation of the Inhibition Properties of Favipiravir and 2'-C-Methyl-Cytidine Triphosphates against Human and Mouse Norovirus RNA Polymerases.Antiviral therapy for respiratory viral infections in immunocompromised patients.Norovirus infection in primary immune deficiency.Cherchez l'Electron.Thiazolides Elicit Anti-Viral Innate Immunity and Reduce HIV Replication.Therapeutics and Immunoprophylaxis Against Noroviruses and Rotaviruses: The Past, Present, and Future.A Review of Clinical Influenza A and B Infections With Reduced Susceptibility to Both Oseltamivir and Zanamivir.Reply to Kempf et al.
P2860
Q26749578-71A40F38-77E8-4452-A935-6B2F996F87A0Q26782746-7499F5FC-F858-407F-8F5E-2F333618C612Q26796360-F195481B-C8F5-4C3A-9B67-9242BDF5081DQ27000668-673BAD57-77D2-4AF3-A11B-02FE6CC5BE95Q28084005-23A9C667-6A02-45D3-918A-940EA940D84DQ29994527-8543919A-7DF6-4693-828E-9707E4A9DCE0Q30145642-DD2CE245-0AD2-461E-BA87-46C853666E2AQ30234943-EB3D2F64-864F-4214-A099-64EFA58C46ECQ30240175-C6129C0D-645F-4A06-B264-41980F1B6FC9Q30240264-A169F205-77C0-47C5-86B5-26C8FE14E958Q30241442-4E22818A-A446-4DEF-ACBB-FBFE8114FECCQ30248209-2E995508-27FD-4A7C-BEA5-AF1C16B4E7B5Q30368680-FDEF25B2-EEA3-4CA5-A784-A90F1D5DBCA1Q30375026-27A7BA5F-5719-42AC-BB1D-05A65D812785Q30377702-B7522DD2-23C6-4D79-B8DB-44C618C57420Q30398099-37402F23-64CE-4A40-9EAB-19D5A253A42BQ33795341-6C05D0D9-16BA-4C2B-A797-6F771AF697DFQ35569547-6B7E5B22-4F40-4B19-A155-8EEDFB08973CQ35763405-EC625188-FBEA-45FF-BBF9-C2DB4DBB423FQ35862004-CC38E830-73D0-4C5A-8FA5-E9E17748A2FBQ36010083-CD5EC9C5-E023-458C-A2E8-266686FC18F8Q36167157-B9936066-DEB9-49C5-95C7-7929097F6657Q37062340-E73D45E0-73E0-4190-8BBE-D528EAE0F11AQ37101808-91C6C1EC-655E-46F4-A097-82A316682C7DQ37517465-8ED297AE-191C-4A1C-A6BA-840A1F4AB0D0Q38158099-5A6A4F05-7712-4565-AF5E-B97495D38154Q38519881-5E295C95-F195-4049-8100-F7FEF2E7A230Q38544126-6B868AEC-41E8-4DCD-B7E2-517B6F8FAD2EQ38603774-8CFF1ECA-E465-4858-8B8A-E7DD2F598EC0Q38744585-FB05FB1D-743A-4734-B898-0DE1C5AF0A1FQ38806842-083EF839-0008-428E-8FF5-F7031AE5AA21Q38817903-EAE04AAA-57A2-491C-AD3C-CB1904899E0FQ38833628-B0F6E3AE-A764-41D7-9CCF-570E905DA2D7Q39076394-FAA293A0-1673-426E-8CC0-1C1B799A3805Q39167685-34B9AAB3-1FB4-4899-A764-DCB4089C62EFQ39286789-9C9D94C8-8DC6-4362-B426-706907CF1AAEQ39717911-055F1B4E-8F9E-4791-9E39-5227CB63E3AEQ40044140-F4339610-5478-41C5-84CA-49F301195714Q40065607-3EE9A322-C68B-46A4-B085-6382DC5CF930Q40265248-29F6ACC5-3970-4867-A9EB-71CF3FA4791B
P2860
Nitazoxanide: a first-in-class broad-spectrum antiviral agent
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Nitazoxanide: a first-in-class broad-spectrum antiviral agent
@ast
Nitazoxanide: a first-in-class broad-spectrum antiviral agent
@en
Nitazoxanide: a first-in-class broad-spectrum antiviral agent
@nl
type
label
Nitazoxanide: a first-in-class broad-spectrum antiviral agent
@ast
Nitazoxanide: a first-in-class broad-spectrum antiviral agent
@en
Nitazoxanide: a first-in-class broad-spectrum antiviral agent
@nl
prefLabel
Nitazoxanide: a first-in-class broad-spectrum antiviral agent
@ast
Nitazoxanide: a first-in-class broad-spectrum antiviral agent
@en
Nitazoxanide: a first-in-class broad-spectrum antiviral agent
@nl
P3181
P1433
P1476
Nitazoxanide: a first-in-class broad-spectrum antiviral agent
@en
P2093
Jean-François Rossignol
P304
P3181
P356
10.1016/J.ANTIVIRAL.2014.07.014
P407
P577
2014-10-01T00:00:00Z